There are currently 88 active clinical trials seeking participants for HIV Infections research studies. The states with the highest number of trials for Autism participants are California, New York, Florida and Texas.
Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults
NCT06039579
Recruiting
The primary purpose of the study is to evaluate the antiviral activity of orally administered VH4004280 and VH4011499 monotherapy over 10 days in human immunodeficiency virus (HIV-1) infected Treatment-Naïve (TN) participants.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/14/2024
Locations: GSK Investigational Site, Bakersfield, California +42 locations
Conditions: HIV Infections
Register for Updates
Peer Supported Collaborative Care Mental Health and Substance Use Disorder Care
NCT04601064
Recruiting
This is a research study to assess the effectiveness of a peer-led collaborative care model for integrating treatment for substance use and or mental health disorders into HIV care settings. Depending on whether or not participants enroll in this study, participants will be assigned randomly (by chance, like drawing a number from a hat) to one of two groups. In group 1, participants would receive usual clinical care. In group 2, participants would work with a peer-case manager who would help su... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
02/09/2024
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: HIV Infections, Substance Use Disorders, Mental Health Disorder, Addiction, Opioid Use, Drug Use
Register for Updates
WiseApp for Spanish Speakers Living With HIV
NCT05398185
Recruiting
This study aims to conduct a 12-month randomized controlled trial to adapt the mobile app, WiseApp, and a smart pill dispenser for Spanish-speaking people living with HIV (PLWH) in the New York City (NYC) area and La Romana, Dominican Republic (DR). The study will assess the efficacy and sustainability of WiseApp as well as identify barriers with its widespread use among Spanish speakers. With disproportionately high rates of HIV in the New York City area and the Dominican Republic, this project... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/30/2024
Locations: Columbia University Irving Medical Center, New York, New York +1 locations
Conditions: HIV Infections, Acquired Immune Deficiency Syndrome, Sexually Transmitted Diseases, Viral
Register for Updates
Tele-Harm Reduction
NCT05208697
Recruiting
The purpose of this study is to test 2 different methods for offering medications that treat HIV, cure Hepatitis C Virus (HCV) (if applicable) and treat substance use disorder (if desired) to people who inject drugs.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Care Resource The SPOT, Fort Lauderdale, Florida +2 locations
Conditions: IV Drug Usage, HIV Infections, Hepatitis C
Register for Updates
Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
NCT04518228
Recruiting
The purpose of this study is to evaluate the pharmacokinetic (PK) properties of antiretroviral (ARV) and anti-tuberculosis (TB) drugs administered during pregnancy and postpartum.
Gender:
Female
Ages:
All
Trial Updated:
01/26/2024
Locations: Usc La Nichd Crs, Los Angeles, California +36 locations
Conditions: HIV Infections, Tuberculosis
Register for Updates
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults
NCT06012136
Recruiting
The primary purpose of the study is to investigate safety and tolerability following single ascending subcutaneous (SC) and intramuscular (IM) doses of capsid inhibitors in healthy participants. The study will also describe the pharmacokinetics following single ascending SC and IM doses of capsid inhibitors in healthy participants.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
01/24/2024
Locations: GSK Investigational Site, Las Vegas, Nevada +1 locations
Conditions: HIV Infections
Register for Updates
Sexual Health Advocacy for Guys - a Text Messaging-based HIV Prevention Program for Guys Who Are Into Guys
NCT06230367
Recruiting
SHAG is a text messaging-based HIV prevention program designed for cisgender sexual minority boys and men 13-20 years of age across the United States. Investigators will test it against a control group that receives messages about healthy lifestyle.
Gender:
Male
Ages:
Between 13 years and 20 years
Trial Updated:
01/19/2024
Locations: Center for Innovative Public Health Research, San Clemente, California +1 locations
Conditions: HIV Infections
Register for Updates
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
NCT05418868
Recruiting
This is an open-label, dose-escalation study to investigate the safety, tolerability, and pharmacokinetics (PK) of single subcutaneous (SC) administration of long acting (LA) Cabotegravir (CAB) 200 milligrams per milliliter (mg/mL) with Recombinant Human Hyaluronidase PH20 (rHuPH20) (Part A) and CAB 400 mg/mL without rHuPH20 (Part C) and CAB 400 mg/mL with rHuPH20 (Part D). Part A of the study (CAB 200 mg/mL with rHuPh20) has been closed to further enrolment based on preliminary results.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
01/05/2024
Locations: GSK Investigational Site, Orlando, Florida +3 locations
Conditions: HIV Infections
Register for Updates
A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories
NCT05514509
Recruiting
The purpose of the study is to evaluate the appropriateness, adoption, feasibility, fidelity, and acceptability of implementation strategies and Cabotegravir (CAB) pre-exposure prophylaxis (PrEP). The study objectives are also to identify barriers and facilitators to implementation. The first of two participant types in the study are the Patient Study Participants (PSPs) will refer to individuals who are enrolled in the study and who will receive commercially available CAB PrEP via prescription... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
12/22/2023
Locations: GSK Investigational Site, Washington, District of Columbia +20 locations
Conditions: HIV Infections
Register for Updates
Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide
NCT04636437
Recruiting
The primary purpose of this study is to see if people with HIV who had a significant weight gain after starting INSTI (integrase strand transfer inhibitor)+TAF/FTC (tenofovir alafenamide/emtricitabine) (TAF/3TC (lamivudine)) regimen could either slow their rate of weight gain or lose weight within about 1 year if they switch to a regimen containing doravirine (DOR; a newer, non-nucleoside reverse transcriptase inhibitor medication). The study will also try to see if participants changing from TA... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/21/2023
Locations: Alabama CRS (31788), Birmingham, Alabama +22 locations
Conditions: HIV Infections
Register for Updates
Testing Integrative Smoking Cessation for HIV Patients
NCT05030766
Recruiting
The purpose of this study is to examine the feasibility, acceptability and effect of a combined smoking cessation intervention integrating contingency management (reward-based) strategies with Mindfulness training to identify the optimal dynamic strategy to promote smoking cessation among HIV patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/21/2023
Locations: University of Miami, Miami, Florida
Conditions: Smoking, Smoking Cessation, HIV Infections
Register for Updates
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
NCT03635788
Recruiting
The purpose of this study is to compare the efficacy, safety, and durability of two different strategies to treat participants with a history of sub-optimal adherence and control of their HIV infection: long-acting (LA) antiretroviral therapy (ART) and all-oral standard of care (SOC).
Gender:
All
Ages:
18 years and above
Trial Updated:
12/14/2023
Locations: Alabama CRS, Birmingham, Alabama +34 locations
Conditions: HIV Infections
Register for Updates